Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1996-05-14
1999-10-05
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Lymphokine
425 852, 425 857, 514 21, 530321, 530323, 530324, A61K 4505
Patent
active
059619694
ABSTRACT:
Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents.
REFERENCES:
patent: 5348739 (1994-09-01), Hellstrand
patent: 5478211 (1995-12-01), Dominiak et al.
Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer, Wiltrout, et al., The Journal of Immunology, 140(9):3261-3265, May 1, 1988.
Interleukin-2: Inception, Impact, and Implications, Smith, Kendall A., Science, 240:1169-1176, May 27, 1988.
Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid, Urba, et al., The Journal of the National Cancer Institute, 80(7):521-525, Jun. 1, 1988.
The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2, Rosenberg, Annals of Surgery, 208(2):121-135, Aug. 1988.
Interleukin 2 as a Pharmacologic Reagent, Lotze, eds., National Institutes of Health, Smith, Chapter 12, pp. 237-245, Oct. 28, 1988.
Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2, Hornung, et al., The Journal of Immunology, 141(10):3671-3679, Nov. 15, 1988.
Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor .alpha. or Interleukin-1 and Interferon-.alpha. or Interleukin-2, .O slashed.stensen, et al., Journal of Biological Response Modifiers, 8:53-61, 1989.
Interleukin-2 can induce suppression of human natural killer cell cytotoxicity, Hellstrand, et al., Clin. Exp. Immunol, 77(3):410-416, 1989.
Biology of Natural Killer Cells Trinchieri, Advances in Immunology, 47:187-376, Accepted for Publication Jan. 23, 1989.
A Phase II Study of Interleukin-2 and Lymphokine-Activated Killer Cells in Patients with Metastatic Malignant Melanoma Dutcher, et al., Journal of Clinical Oncology, 7(4):477-485, Apr. 1989.
Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN-.gamma., Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor-.alpha., and Histamine-Releasing Factors on the Secretion of Histamine From Basophils, Alam, et al., The Journal of Immunology, 142(10):3431-3435, May 18, 1989.
Activation of Natural Killer Cells via the p75 Interleukin 2 Receptor, Phillips, et al., J. Exp. Med., 170:291-296, Jul. 1989.
Inhibition of Lymphokine-Activated Killer- and Natural Killer-Mediated Cytotoxicities by Neutrophils, Shau, et al., The Journal of Immunology, 143(3):1066-1072, Aug. 1989.
Regulation of Human Basophil Mediator Release by Cytokines, Schleimer, et al., The Journal of Immunology, 143(4):1310-1317, Aug. 15, 1989.
Inhibition of Lymphokine-activated Killer Cell Function by Human Alveolar Macrophages, Roth, et al., Cancer Research, 49:4690-4695, Sep. 1989.
A Cell-to-Cell Mediated Interaction Involving Monocytes and Non.sup.- T/CD16.sup.+ Natural Killer (NK) Cells is Required for Histamine H.sub.2 -Receptor-Mediated NK-Cell Activation, Hellstrand, et al., Scand J. Immunol, 31:631-644, 1990.
Deficiency in Catalase Activity Correlates with the Appearance of Tumor Phenotype in Human Keratinocytes, Rabilloud, et al., Int. J. Cancer, 45:952-956, 1990.
Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD16.sup.+ NK Cells, Accessory Monocytes, and 5-HT.sub.1A Receptors, Hellstrand, et al., Cellular Immunology, 127:199-214, 1990.
Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells, Damia, et al., Cancer Immunol Immunother, 32:241-244, 1990.
Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation, Hellstrand, et al., Scand J. Immunol, 32(2):183-192, 1990.
Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells, Okamoto, et al., Immunology, 70:186-190, 1990.
Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2, Hellstrand, et al., Int. Arch. Allergy Appl. Immunology, 92:379-389, 1990.
Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy, Tom Smith, MD, Comprehensive Therapy, 16(1):8-13, 1990.
Splenic Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases, Mavligit, et al., Journal of Clinical Oncology, 8(2):319-324, 1990.
Renal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon, Krigel, et al., Journal of Clinical Oncology, 8(3):460-467, Mar. 1990.
High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma, Abrams, et al., Journal of the National Cancer Institute, 82(14):1202-1206, Jul. 18, 1990.
Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial, Dilman, et al., Journal of the National Cancer Institute, 82(16):1345-1348, Aug. 15, 1990.
Immunological Effects of Flavone Acetic Acid, Triozzi, et al., Cancer Research, 50:6483-6485, Oct. 15, 1990.
Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells, Hellstrand, et al., The Journal of Immunology, 145(12):4366-4370, Dec. 15, 1990.
Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study Foa, et al., British Journal of Haematology, 77:491-496, 1991.
Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H.sub.2 -Receptors, Hellstrand, et al., Scand J. Immunol, 34:741-752, 1991.
Induction of Natural Killer Activity by Xanthenone Analogues of Flavone Acetic Acid: Relation with Antitumour Activity, Ching, et al., Eur. J. Cancer, 27(1):79-83, 1991.
In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthenone Analogues of Flavone Acetic Acid, Ching, et al., Eur. J. Cancer, 27(12):1684-1689, 1991.
Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H.sub.2 -Receptors, Hellstrand, et al., Cellular Immunology, 138:44-45, 1991.
Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with Flavone acetic acid (FAA), Galligioni, Annals of Oncology, 2:145-150, 1991.
Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells, Szatrowski, et al., Cancer Research, 51:794-798, Feb. 1991.
A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients With Metastatic Melanoma, Dutcher, et al., Journal of Clinical Oncology, 9(4):641-648, Apr. 1991.
Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial, Dillman, et al., Journal of Clinical Oncology, 9(7):1233-1240, Jul. 1991.
Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastatic Melanoma: A Multicenter Phase II Study, Stoter, et al., Journal of Clinical Oncology, 9(9):1687-1691, Sep. 1991.
Interactions between human monocytes and tumor cells. Monocytes can either enhance or inhibit the growth and survival of K562 Cells, Davies, et al., Nov. 1991.
Effects of Flavonoids on Immune and Inflammatory Cell Functions, Middleton, et al., Biochemical Pharmacology, 43(6):1167-1179, 1992.
Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2 Khoo, et al., C
Hellstrand Kristoffer
Hermodsson Svante
Delaney Patrick R.
Maxim Pharmaceuticals, Inc.
Tsang Cecilia J.
LandOfFree
Stable circulating histamine levels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable circulating histamine levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable circulating histamine levels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1168267